Post-treatment control of HIV infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 17, 2015, Pages 5467-5472

  Conway, Jessica M ^a,b   Perelson, Alan S ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

HIV latency; HIV viral rebound; Immune exhaustion; Mathematical modeling

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INFECTION CONTROL; LATENT PERIOD; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; PRIMARY INFECTION; PRIORITY JOURNAL; REBOUND; SECONDARY PREVENTION; TREATMENT DURATION; VIRUS LOAD; BIOLOGICAL MODEL; CD8+ T LYMPHOCYTE; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PHYSIOLOGY; VIRUS LATENCY;

ADAPTIVE IMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, IMMUNOLOGICAL; VIRUS LATENCY;

EID: 84928718905     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1419162112     Document Type: Article

References (72)

1. Sáez-Cirión A, et al.; ANRS VISCONTI Study Group (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 9(3):e1003211.
2. Goujard C, et al.; ANRS CO6 PRIMO Study Group (2012) HIV-1 control after transient antiretroviral treatment initiated in primary infection: Role of patient characteristics and effect of therapy. Antivir Ther 17(6):1001-1009.
3. Salgado M, et al. (2011) Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology 8:97.
4. Lafeuillade A (August 5, 2014) General Hospital reveals fourteen years of HIV functional cure: The case of the 'Toulon Patient'. PR Newswire. Available at article.wn.com/view/2014/08/05/General-Hospital-Reveals-Fourteen-Years-of-HIV-Functional-Cu/.
5. Stöhr W, et al. (2013) Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE 8(10):e78287.
6. Lambotte O, et al.; SEROCO-HEMOCO Study Group (2005) HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41(7):1053-1056.
7. O'Connell KA, Bailey JR, Blankson JN (2009) Elucidating the elite: Mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30(12):631-637.
8. Blankson JN (2010) Effector mechanisms in HIV-1 infected elite controllers: Highly active immune responses? Antiviral Res 85(1):295-302.
9. Walker BD (2007) Elite control of HIV infection: Implications for vaccines and treatment. Top HIV Med 15(4):134-136.
10. Sáez-Cirión A, et al.; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104(16):6776-6781.
11. Okulicz JF, et al.; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200(11):1714-1723.
12. Grabar S, et al. (2009) Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 23(9):1163-1169.
13. Richman DD, et al. (2009) The challenge of finding a cure for HIV infection. Science 323(5919):1304-1307.
14. Chomont N, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15(8):893-900.
15. Chun TW, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95(15):8869-8873.
16. Ananworanich J, et al.; RV254/SEARCH 010 Study Group (2012) Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 7(3):e33948.
17. Whitney JB, et al. (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512(7512):74-77.
18. Chun TW, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629):183-188.
19. Eriksson S, et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9(2):e1003174.
20. Siliciano JD, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9(6):727-728.
21. Fondère J-M, et al. (2004) Enumeration of latently infected CD4+ T cells from HIV-1-infected patients using an HIV-1 antigen ELISPOT assay. J Clin Virol 29(1):33-38.
22. Ho YC, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155(3):540-551.
23. Ramratnam B, et al. (2000) The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6(1):82-85.
24. Conway JM, Coombs D (2011) A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients. PLOS Comput Biol 7(4):e1002033.
25. Rong L, Perelson AS (2009) Modeling latently infected cell activation: Viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLOS Comput Biol 5(10):e1000533.
26. Rong L, Perelson AS (2009) Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 260(2):308-331.
27. Hocqueloux L, et al.; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) (2013) Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 68(5):1169-1178.
28. Fiebig EW, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV infection. AIDS 17(13):1871-1879.
29. Keele BF, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21):7552-7557.
30. Shytaj IL, et al. (2012) A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 8(6):e1002774.
31. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255):1582-1586.
32. Perelson AS, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387(6629):188-191.
33. Nowak MA, May R (2001) Virus Dynamics: Mathematical Principles of Immunology and Virology (Oxford Univ Press, London).
34. Adams BM, Banks HT, Davidian M, Rosenberg ES (2007) Estimation and prediction with HIV-treatment interruption data. Bull Math Biol 69(2):563-584.
35. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF (2000) Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS 14(15):2313-2322.
36. Khaitan A, Unutmaz D (2011) Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep 8(1):4-11.
37. Kaufmann DE, Walker BD (2009) PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182(10):5891-5897.
38. Rong L, Perelson AS (2009) Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci 217(1):77-87.
39. Johnson PLF, et al. (2011) Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. J Virol 85(11):5565-5570.
40. Archin NM, et al. (2012) Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA 109(24):9523-9528.
41. Stafford MA, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203(3):285-301.
42. Vaidya NK, et al. (2010) Treatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral load. PLOS Comput Biol 6(11):e1001012.
43. De Boer RJ, Perelson AS (2013) Quantifying T lymphocyte turnover. J Theor Biol 327:45-87.
44. Westera L, et al. (2013) Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans. Blood 122(13):2205-2212.
45. Bailey JR, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80(13):6441-6457.
46. Conway JM, Konrad BP, Coombs D (2013) Stochastic analysis of pre- and postexposure prophylaxis against HIV infection. SIAM J Appl Math 73(2):904-928.
47. Pearson JE, Krapivsky P, Perelson AS (2011) Stochastic theory of early viral infection: Continuous versus burst production of virions. PLOS Comput Biol 7(2):e1001058.
48. Tuckwell HC, Le Corfec E (1998) A stochastic model for early HIV-1 population dynamics. J Theor Biol 195(4):451-463.
49. Davenport MP, Ribeiro RM, Perelson AS (2004) Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol 78(18):10096-10103.
50. Markowitz M, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77(8):5037-5038.
51. Hill AL, Rosenbloom DIS, Fu F, Nowak MA, Siliciano RF (2014) Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 111(37):13475-13480.
52. Persaud D, et al. (2013) Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 369(19):1828-1835.
53. NIH News (July 10, 2014) "Mississippi baby " now has detectable HIV, researchers find. National Institutes of Health News . Available at www.niaid.nih.gov/news/newsreleases/2014/pages/mississippibabyhiv.aspx.
54. Bowman M-C, Archin NM, Margolis DM (2009) Pharmaceutical approaches to eradication of persistent HIV infection. Expert Rev Mol Med 11:e6.
55. Violari A, et al.; CHER Study Team (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359(21):2233-2244.
56. Kim H, Perelson AS (2006) Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLOS Comput Biol 2(10):e135.
57. Chun TW, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: Implications for eradication. AIDS 24(18):2803-2808.
58. Iwami S, Nakaoka S, Takeuchi Y, Miura Y, Miura T (2009) Immune impairment thresholds in HIV infection. Immunol Lett 123(2):149-154.
59. Altes HK, Wodarz D, Jansen VAA (2002) The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination. J Theor Biol 214(4):633-646.
60. Korthals Altes H, Ribeiro RM, de Boer RJ (2003) The race between initial T-helper expansion and virus growth upon HIV infection influences polyclonality of the response and viral set-point. Proc Biol Sci 270(1522):1349-1358.
61. Henrich TJ, et al. (2014) HIV-1 rebound following allogeneic stem cell transplantation and treatment interruption. Top Antiviral Med 22(e-1):71-72.
62. Henrich TJ, et al. (2013) Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 207(11):1694-1702.
63. Moir S, Fauci AS (2013) Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev 254(1):207-224.
64. Kwong PD, Mascola JR, Nabel GJ (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: The end of the beginning. Nat Rev Immunol 13(9):693-701.
65. Tomaras GD, et al. (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 82(24):12449-12463.
66. García F, et al. (2013) Dendritic cell based vaccines for HIV infection: The way ahead. Hum Vaccin Immunother 9(11):2445-2452.
67. Ramirez LA, Arango T, Boyer J (2013) Therapeutic and prophylactic DNA vaccines for HIV-1. Expert Opin Biol Ther 13(4):563-573.
68. Archin NM, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482-485.
69. Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E (2013) Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 21(6):277-285.
70. Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 5(6):e1000495.
71. Xing S, et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85(12):6060-6064.
72. Archin NM, Margolis DM (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27(1):29-35.